DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Peter Welford - 1 Welford - 1 AstraZeneca's - 1 Jefferies - 1 AstraZeneca's eplontersen - 1 transthyretin - 1 deruxtecan - 1 Pascal Soriot's - 1
Top related locs:
Japan's Daiichi British Biotech of China London Frankfurt Bengaluru
Top related orgs:
AstraZeneca - 2 Japan's - 2 Jefferies - 1 AstraZeneca's - 1 pharma - 1 Merck & Co - 1 Biotech of - 1 Barclays - 1

Search resuls for: "Japan's Daiichi"


3 mentions found


☆ Jefferies upgrades this pharma stock, citing overlooked 'blockbuster' drug opportunities
  + stars: | 2023-09-25 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
AstraZeneca's tozorakimab drug for chronic obstructive pulmonary disease also seems underappreciated, with a potential to reach $4.5 billion in peak sales, according to Jefferies. The firm also suggests up to $3.5 billion in sales for AstraZeneca's eplontersen , a drug aimed at treating hereditary transthyretin-mediated amyloid polyneuropathy. The pharmaceutical giant is also poised to be the frontrunner in breast cancer treatments. Another one of AstraZeneca's breast cancer therapies, also being developed with Daiichi Sankyo, came out with positive news Friday. Its experimental precision drug datopotamab deruxtecan demonstrated an improvement in slowing the progression of a common type of breast cancer in a late-stage trial.
Persons: Peter Welford, Welford, AstraZeneca's, Jefferies, AstraZeneca's eplontersen, transthyretin, deruxtecan, Pascal Soriot's, — CNBC's Michael Bloom Organizations: AstraZeneca, Jefferies, AstraZeneca's, Japan's, pharma Locations: Japan's Daiichi
☆ AstraZeneca shares drop as lung cancer trial update lags expectations
  + stars: | 2023-07-03 | by ( Maggie Fick Ludwig Burger | Maggie Fick | Ludwig Burger | ) www.reuters.com   time to read: +3 min
July 3 (Reuters) - AstraZeneca (AZN.L) said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped. It declined to provide more trial details, saying they would be presented at an as yet undisclosed medical conference. At 0855 GMT, shares in AstraZeneca were down 5.8% at their lowest level in more than three months. Gilead (GILD.O) has pioneered the targeting of TROP2 with an ADC named Trodelvy, approved to treat certain types of breast and bladder cancer. AstraZeneca said that the datopotamab deruxtecan trial would continue as planned to assess the effect of the drug on overall survival of patients, another important efficacy criterion.
Persons: datopotamab, AstraZeneca, British drugmaker, Kelun, Maggie Fick, Ludwig Burger, Sinchita Mitra, Lucy Raitano, Krishna Chandra Eluri, Susan Fenton Organizations: AstraZeneca, Japan's, Merck & Co, Biotech of, Barclays, Thomson Locations: British, Biotech of China, London, Frankfurt, Bengaluru
☆ Japan's Daiichi Sankyo says mRNA COVID vaccine successful in booster trial
  + stars: | 2022-11-15 | by ( ) www.reuters.com   time to read: +1 min
TOKYO, Nov 15 (Reuters) - Japan's Daiichi Sankyo Co (4568.T) said on Tuesday its mRNA-based COVID-19 vaccine had reached its primary endpoint in a trial of the shot as a booster. Based on the results, Daiichi Sankyo will file a new-drug application to regulators in January 2023. Approval would give Japan a home-grown source for mRNA vaccines, which have made up the bulk of its COVID inoculations to date. Japan has relied on imports of shots developed by U.S.-based drugmakers Pfizer Inc (PFE.N) and Moderna Inc (MRNA.O). Daiichi Sankyo's shares jumped on the news, rising 3.3% versus a 0.1% advance in the benchmark Nikkei (.n225) gauge.
0 next >>
Total: 3